RecruitingNot Applicable

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

United States50 participantsStarted 2024-12-10

Plain-language summary

Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients aged between 18 and 90 years of age * Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40-50%) * Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure Exclusion Criteria: * Unable to interrupt VKA anticoagulation * Point of care International Normalized Ratio (INR) \> 1.5 * Pregnant patients * Acute hospitalization or decompensation within 2 weeks prior to study date * Participation in a study involving an investigational drug within 4 weeks prior to study date * Inability to lie flat in the supine position * Symptomatic hemodynamic instability at rest or during the procedure

What they're measuring

Diagnostic accuracy based on Area Under Curve (AUC)

Timeframe: 5 years

Trial details

NCT IDNCT06299436

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2029-03-31

Contact for this trial

Steven Hsu, MD

410-502-0955 steven.hsu@jhmi.edu